Mantle Cell Lymphoma (MCL) Completed Phase 1 / 2 Trials for Rituximab (DB00073)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00963534Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.Treatment
NCT01078142Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaTreatment
NCT00633594Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaTreatment
NCT01851551Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLTreatment